{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE325nnn/GSE325304/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE325304"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Antigen-Specific mRNA–LNP Vaccination with mTOR Inhibition Promotes Treg Cells and Limits Allergy","description":"Immune tolerance to T helper 2 (Th2)-mediated allergic reactions relies largely on antigen-specific T helper 1 (Th1) and regulatory T cells, which modulate downstream immune responses upon antigen exposure and mitigate allergic diseases. While allergen-encoded mRNA-lipid nanoparticle (mRNA-LNP) vaccine elicits Th1 and cytotoxic CD8+ T responses that counterbalance Th2 immunity, co-administration of mRNA-LNP with an mTOR inhibitor shifts this profile by promoting generation of functional regulatory T cells and partially attenuating Th1 and CD8+ T cell responses. In pre-clinical models of allergic asthma, this combinatorial strategy preserved the anti-allergic effects of mRNA-LNP immunization, reduced eosinophil activation markers, and limited vaccine-associated cytotoxicity. The ability of an mTOR inhibitor to profoundly modify mRNA-LNP vaccination by inducing regulatory T cells presents a potential strategy to enhance regulatory immunity in the treatment of allergy and other inflammatory diseases.","dates":{"publication":"2026/05/20"},"accession":"GSE325304","cross_references":{"GSM":["GSM9600291","GSM9600292"],"GPL":["24247"],"GSE":["325304"],"taxon":["Mus musculus"]}}